EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Jie-Syuan Wu iD, Lee-Yuan Lin iD, Jia-Wei Sun iD, Wei-Ting Yu, Fara Silvia Yuliani iD, Shyh-Hsiang Lin iD

Obesity · 2026

DOI: 10.1002/oby.70218 ↗

At a glance

Journal article in Obesity, 2026. Written by Jie-Syuan Wu and 5 co-authors. Institution: School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Osteoporosis, Anti-Obesity Agents. Cited 3 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.

Methods

This retrospective cohort study included deidentified TriNetX data on ≥ 50‐year‐old nondiabetic adults with obesity. After 1:1 propensity score matching on demographic, clinical, and laboratory covariates, 18,062 GLP‐1 RA users were compared with non‐GLP‐1 medication users. The primary outcome was incident osteoporosis; secondary outcomes included major osteoporotic fractures, cervical and thoracolumbar disc disorders, and osteoarthritis.

Results

GLP‐1 RA use was associated with lower risks of osteoporosis (relative risk [RR] 0.48; 95% CI, 0.43–0.52; number needed to treat [NNT] = 28), major osteoporotic fractures (RR 0.15; 95% CI, 0.11–0.22; NNT = 88), cervical disc degeneration (RR 0.34; 95% CI, 0.28–0.41; NNT = 63), thoracolumbar disc disease (RR 0.36; 95% CI, 0.33–0.40; NNT = 20), and osteoarthritis (RR 0.45; 95% CI, 0.43–0.48; NNT = 9). Protective associations were consistent across age, sex, BMI, and drug subtype subgroups and remained robust in sensitivity analyses.

Conclusions

GLP‐1 RA use was associated with favorable musculoskeletal outcomes, including lower risks of osteoporosis and fractures, in nondiabetic adults with obesity compared with other obesity medications.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityOsteoporosisAnti-Obesity AgentsHumansFemaleMiddle AgedMaleRetrospective StudiesAgedOsteoarthritisOsteoporotic FracturesIntervertebral Disc Degeneration

Author keywords

glucagon‐like peptide‐1 receptor agonistsobesityosteoporosisweight loss

Substances

Glucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity Agents

Authors and institutions

  • School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • School of Nutrition, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
  • School of Food Safety, College of Nutrition, Taipei Medical University, Taipei, Taiwan.

ORCID profiles: Jie-Syuan Wu, Lee-Yuan Lin, Jia-Wei Sun, Fara Silvia Yuliani, Shyh-Hsiang Lin

Cite

APA

Wu, J. S., Lin, L. Y., Sun, J. W., Yu, W. T., Yuliani, F. S., & Lin, S. H. (2026). Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults. Obesity. https://doi.org/10.1002/oby.70218

Vancouver

Wu JS, Lin LY, Sun JW, Yu WT, Yuliani FS, Lin SH. Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults. Obesity. 2026. doi:10.1002/oby.70218

BibTeX
@article{Wu2026,
  author = {Wu, Jie-Syuan and Lin, Lee-Yuan and Sun, Jia-Wei and Yu, Wei-Ting and Yuliani, Fara Silvia and Lin, Shyh-Hsiang},
  title = {Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70218}
}
Start for free →